FOLH1 and posterior cortical atrophy: Currently, PSMA based-177Lu RLT engaged either PSMA ligand 617 (159) or PSMA I&T (imaging and therapy) (160) and delivered β particles to the PSMA+ cells and the adjacent TME as a novel theragnostic strategy for advanced PCa (161) (Table 3).